BioNTech sues Moderna for patent infringement over COVID-19 shots [BNN Bloomberg (Canada)]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: BNN Bloomberg
The lawsuit said that mNEXSPIKE, Moderna's next-generation COVID shot approved by the U.S. Food and Drug Administration in 2025, violates BioNTech's rights in technology for a streamlined messenger RNA-based vaccine design that can be given to patients at a lower dosage. Moderna sued BioNTech and its partner Pfizer for patent infringement over Comirnaty in 2022, in a lawsuit that is ongoing. The cases are among a wave of patent lawsuits from biotech companies seeking royalties for the technology used in the blockbuster vaccines. A Moderna spokesperson said that the company would defend itself against BioNTech's case. BioNTech did not immediately respond to a request for comment on the new lawsuit. Spokespeople for Pfizer, which is not directly involved in the lawsuit, also did not immediately comment. mNEXSPIKE is expected to account for 55% of Moderna's COVID vaccine revenue through the 2025-26 respiratory virus season, BioNTech's lawsuit said. COVID vaccine revenues have
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Where is Pfizer Inc. (PFE) Headed? [Yahoo! Finance]Yahoo! Finance
- Pfizer (NYSE:PFE) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock.MarketBeat
- ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJMBusiness Wire
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game [Seeking Alpha]Seeking Alpha
- Pfizer: The Rebound Looks Unsustainable [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 2/17/26 - Form 4
- 2/12/26 - Form 13F-HR
- 2/3/26 - Form 8-K
- PFE's page on the SEC website